Dr. Michael Tarantino, Medical Director and Founder of the Bleeding and Clotting Disorders Institute, is considered one of the world’s thought leaders on immune thrombocytopenia (ITP). He has published dozens of papers on ITP in major medical journals over the past 25 years.
In a recent issue of the Journal of Blood Medicine (J Blood Med. 2015; 6: 37-44. Published online 2015 Jan 19. doi: 10.2147/JBM.S47240), Dr. Tarantino and resident physician, Sarah Chalmers, MD reviewed the current knowledge on the treatment of ITP with a relatively new agent that helps the body grow enough platelets to counteract the premature destruction of platelets seen in patients with ITP. Dr. Tarantino and the clinical staff at BCDI have been involved in clinical research of this and other “platelet growth factors” for the past ten years. Read review here